Trifluridine

Revision as of 21:53, 30 December 2013 by Gerald Chi (talk | contribs) (Changed protection level for "Trifluridine" ([Edit=Allow only autoconfirmed users] (expires 21:53, 6 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 21:53, 6 January 2014 (UTC))))
Jump to navigation Jump to search
Trifluridine
File:Trifluridine.svg
Clinical data
Routes of
administration
Eye drops
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life12 minutes
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H11F3N2O5
Molar mass296.2 g/mol

Trifluridine is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals.

It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the -CF3 group added to the uracil component blocks base pairing.

External links

  • Costin D, Dogaru M, Popa A, Cijevschi I. "Trifluridine therapy in herpetic in keratitis". Rev Med Chir Soc Med Nat Iasi. 108 (2): 409–12. PMID 15688823.
  • Kuster P, Taravella M, Gelinas M, Stepp P (1998). "Delivery of trifluridine to human cornea and aqueous using collagen shields". CLAO J. 24 (2): 122–4. PMID 9571274.
  • O'Brien W, Taylor J (1991). "Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents". Invest Ophthalmol Vis Sci. 32 (9): 2455–61. PMID 1907950.
  • "Trifluridine Opthalmic Solution, 1%" (PDF). Retrieved 2007-03-24.